The P2B mid-term analysis did not occur because th

The P2B mid-term analysis did not occur because the trial took longer than expected to recruit for. When the interim analysis was due only a percentage, call it halfish, of patients had been enrolled but many of those had completed treatment and followup. As a result, they would have been unblinding the final results on whatever number of patients were done at the time. This would have damaged the integrity of the blind for patients not yet recruited. I don't think this has any bearing on whether the data available at the time was good, bad or otherwise.

It makes sense to me as you wouldn't want new patients in a blinded placebo-controlled trial to know how the drug has already worked on 40 people.

I don't read anything into it other than the fact that recruitment took much longer than expected.